Prostate cancer often presents unique challenges to patients and physicians alike. It can be indolent and nonaggressive — or life-threatening and everything in between. Unlike most cancers that have a dedicated road map for treatment, prostate cancer revolves around opinions and biases.What's this item about? What makes it interesting? Write a catchy description to grab your audience's attention...
A study published Wednesday in the American Journal of Preventive Medicinecaptured a snapshot of the attitudes black men have regarding prostate cancer research and the evolving field of genomic testing, finding significant mistrust of the healthcare system and medical research.
American doctors are successfully persuading increasing numbers of men with low-risk prostate cancer to reject immediate surgery and radiation in favor of surveillance, a trend that is sparing men's sexual health without increasing their risk of death.
Cigna becomes the first US insurer to cover HIFU for prostate cancer
April 18, 2018
Cigna, a global health insurance service company based in the US, announced that patients in the United States who have localized radio-recurrent prostate cancer are potentially eligible for insurance coverage for HIFU treatment.
HIFU utilizes ultrasound waves to destroy cancer cells with no damage to surrounding tissue. To date it is not covered by most insurance but the outcomes are quite remarkable and efforts are being made to improve insurance participation. Learn more about HIFU.
Phil Chenier was treated for prostate cancer in 2004 and again in 2016, each time based on elevated PSA readings and follow-up exams. Fortunately with regular checkups, he had the benefit of early detection, and on both occasions he had the support from friends familiar with the disease that helped him face this head on.
While patients with very low-risk prostate cancer may be treated with active surveillance (AS), reducing over-treatment and treatment-related complications, a new study shows that only one in four patients in this group actually opt for this treatment.
Study finds MRI and MRI-guided biopsy cheaper long-term than standard ultrasound.
A diagnostic MRI followed by one of three MRI-guided biopsy strategies is a cost-effective method to detect prostate cancer, according to a new study out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center.
The anxiety many men experience after being diagnosed with prostate cancer may lead them to choose potentially unnecessary treatment options, researchers report.
“Emotional distress may motivate men with low-risk prostate cancer to choose more aggressive treatment, such as choosing surgery over active surveillance,” says the study’s lead author, Heather Orom, associate professor of community health and health behavior in the University at Buffalo’s School of Public Health and Health Professions.
Giving men with suspected prostate cancer an MRI scan could improve diagnosis and save those who do not have aggressive cancers from having an unnecessary biopsy, according to a study published in The Lancet.
The study estimates that adding the extra test could help one in four (27%) men avoid an unnecessary biopsy and reduce the number of men who are over-diagnosed – diagnosed with a cancer that does not go on to cause any harm during their lifetime – by 5%.
Men hoping to avoid some side effects of prostate cancer treatment are shelling out tens of thousands of dollars for a procedure whose long-term effects are unknown and insurers, including Medicare, won’t pay for.(continue)
The survival rate for early-stage prostate cancer is 99 percent after 10 years, regardless of whether men undergo surgery, radiation or are "actively monitored," according to studies published Wednesday. Researchers hailed the results as good news, saying they had been expecting a survival rate of 90 percent. (continue)